Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C12H13NO5S |
| Molecular Weight | 283.3 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(=O)N[C@@H](CSC(=O)C1=CC=CC=C1O)C(O)=O
InChI
InChIKey=VYPKEODFNOEZGS-VIFPVBQESA-N
InChI=1S/C12H13NO5S/c1-7(14)13-9(11(16)17)6-19-12(18)8-4-2-3-5-10(8)15/h2-5,9,15H,6H2,1H3,(H,13,14)(H,16,17)/t9-/m0/s1
| Molecular Formula | C12H13NO5S |
| Molecular Weight | 283.3 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
DescriptionSources: https://adisinsight.springer.com/drugs/800006855
Sources: https://adisinsight.springer.com/drugs/800006855
Salnacedin (also known as G 201) was developed as a topical anti-inflammatory agent; Salnacedin participated in phase II clinical trials in the USA for the treatment of dermatitis, acne, and psoriasis. However, all these studies were discontinued.
Originator
Approval Year
Sample Use Guides
In Vivo Use Guide
Sources: https://adisinsight.springer.com/drugs/800006855
Unknown
Route of Administration:
Topical
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:12:50 GMT 2025
by
admin
on
Mon Mar 31 18:12:50 GMT 2025
|
| Record UNII |
02X9QIP2NU
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C275
Created by
admin on Mon Mar 31 18:12:50 GMT 2025 , Edited by admin on Mon Mar 31 18:12:50 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
87573-01-1
Created by
admin on Mon Mar 31 18:12:50 GMT 2025 , Edited by admin on Mon Mar 31 18:12:50 GMT 2025
|
PRIMARY | |||
|
3058743
Created by
admin on Mon Mar 31 18:12:50 GMT 2025 , Edited by admin on Mon Mar 31 18:12:50 GMT 2025
|
PRIMARY | |||
|
7351
Created by
admin on Mon Mar 31 18:12:50 GMT 2025 , Edited by admin on Mon Mar 31 18:12:50 GMT 2025
|
PRIMARY | |||
|
GG-20
Created by
admin on Mon Mar 31 18:12:50 GMT 2025 , Edited by admin on Mon Mar 31 18:12:50 GMT 2025
|
PRIMARY | |||
|
CHEMBL2106981
Created by
admin on Mon Mar 31 18:12:50 GMT 2025 , Edited by admin on Mon Mar 31 18:12:50 GMT 2025
|
PRIMARY | |||
|
DTXSID00236468
Created by
admin on Mon Mar 31 18:12:50 GMT 2025 , Edited by admin on Mon Mar 31 18:12:50 GMT 2025
|
PRIMARY | |||
|
C152289
Created by
admin on Mon Mar 31 18:12:50 GMT 2025 , Edited by admin on Mon Mar 31 18:12:50 GMT 2025
|
PRIMARY | |||
|
02X9QIP2NU
Created by
admin on Mon Mar 31 18:12:50 GMT 2025 , Edited by admin on Mon Mar 31 18:12:50 GMT 2025
|
PRIMARY | |||
|
SUB10432MIG
Created by
admin on Mon Mar 31 18:12:50 GMT 2025 , Edited by admin on Mon Mar 31 18:12:50 GMT 2025
|
PRIMARY | |||
|
100000080528
Created by
admin on Mon Mar 31 18:12:50 GMT 2025 , Edited by admin on Mon Mar 31 18:12:50 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |